CHPA released the following statement today in support of a Florida law prohibiting the sale of OTC medicines containing the cough suppressant dextromethorphan (DXM) to minors.
In general, CHPA supports FDA's intent to harmonize the requirements for Rx and OTC products and make them consistent with long-standing Agency policy.
CHPA appreciates the opportunity to provide information on features to add and potential functionality improvements to make the Dietary Supplement Label Database a more useful tool for regulators, consumers, and other users of the database.
CHPA supports improving the compendial test methods and establishing product standards for the variety of dosage forms, which can provide an additional measure of safety for OTC products.
CRN, CHPA, and their member companies are concerned with and offer the following comments to the proposed revisions to the USP-NF General Chapter <467> on Residual Solvents.
Our member companies support the concept that well-designed metrics are critical in driving and measuring continuous improvement activities in both quality systems and improving manufacturing processes.
CHPA appreciates the opportunity to provide information relevant to the assessment of the evidence of the potential developmental neurotoxicity of fluoride.
